DWA
XENE icon

Dorsey Wright & Associates’s Xenon Pharmaceuticals XENE Stock Holding History

Dorsey Wright & Associates’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-674
Closed -$9K – 372
2020
Q2 		$9K Hold
674
– – ﹤0.01% 289
2020
Q1 		$8K Buy
+674
New +$9.6K ﹤0.01% 206
2018
Q4 		– Sell
-1,184
Closed -$16K – 355
2018
Q3 		$16K Buy
+1,184
New +$13.7K ﹤0.01% 209

Other funds holding XENE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dorsey Wright & Associates's XENE Position: Q3 2020 in Review

Dorsey Wright & Associates sold out of Xenon Pharmaceuticals (XENE) in Q3 2020, closing a stake of 674 shares — an estimated $9K sold.

Dorsey Wright & Associates first reported a position in XENE in Q3 2018 and held it in 3 quarters. The position peaked at $16K in Q3 2018. 80 funds tracked by Wall St. Rank hold XENE as of Q3 2020.

  • Dorsey Wright & Associates reported no remaining Xenon Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 674 Xenon Pharmaceuticals shares in Q3 2020, an estimated $9K.
  • Dorsey Wright & Associates first reported a position in Xenon Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • Dorsey Wright & Associates's Xenon Pharmaceuticals position peaked at $16K in Q3 2018.
  • 80 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2020.

Based on Dorsey Wright & Associates's 13F filing for Q3 2020, filed 28 Oct 2020.